|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, the T45G polymorphism of the adiponectin gene may not constitute an NAFLD risk factor.
|
26909902 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ADIPOQ G rs266729 and TNF- 308 A allele are associated with obesity, MetS/NAFLD and insulin resistance.
|
31659105 |
2020 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
There was also a significant association between the G variant of AdipoQ rs1501299 G>T polymorphism and an increased risk of NAFLD.
|
25385252 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis suggests that adiponectin +45T>G and -11377C>G polymorphisms might be a risk factor for NAFLD, while +276G>T polymorphism may be a protective factor for NAFLD among Asians.
|
24548122 |
2014 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
RESULTS Eight qualified case-control studies with 1639 patients and 1426 controls demonstrated a significant correlation between rs1501299 polymorphism in adiponectin and NAFLD under the dominant model (OR=1.18, 95% CI=1.02-1.36), allelic contrast (OR=1.21, 95% CI=1.09-1.36), homozygote comparison (OR=1.63, 95% CI=1.26-2.01) and the recessive allele model (OR=1.58, 95% CI=1.23-2.02) with evident heterogeneity.
|
30735485 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Correlation between adiponectin polymorphisms and non-alcoholic fatty liver disease with or without metabolic syndrome in Chinese population.
|
19246975 |
2008 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of adiponectin gene polymorphisms and additional gene-gene interaction with nonalcoholic fatty liver disease in the Chinese Han population.
|
26865047 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The tagSNPs rs2241767, rs1501299 and rs3774261 in the adiponectin gene are risk factors for the individuals' susceptibility to and progression of NAFLD.
|
26334200 |
2015 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
ADPN I148M polymorphism has been consistently reported to play a role in liver-associated diseases, such as alcoholic liver disease, chronic hepatitis C, and liver fat and fibrosis in nonalcoholic fatty liver disease.
|
26632699 |
2015 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We also examined nine polymorphisms on six non-alcoholic fatty liver disease-related candidate genes (ADIPOQ, APOC3, GCKR, LEPR, PNPLA3, and PPARG).
|
27547913 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our meta-analysis results revealed that ADIPOQ gene +276G>T polymorphism was not associated with NAFLD under various genetic models (allele model: OR = 0.99, 95% CI [0.69, 1.41]; dominant model: OR = 1.06, 95% CI [0.71, 1.58]; recessive model: OR = 0.83, 95% CI [0.42, 1.65]; homozygous model: OR = 0.86, 95% CI [0.38, 1.95]; heterozygous model: OR = 1.10, 95% CI [0.80, 1.53]; respectively).
|
30838812 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We hypothesized adiponectin polymorphisms may predispose to NAFLD and may increase cardiovascular risk by modulating circulating lipoprotein and adiponectin response postprandially.
|
18311774 |
2008 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The gene polymorphisms of adiponectin-encoding gene (ADIPOQ), leptin receptor (LEPR), apolipoprotein C3 (APOC3), peroxisome proliferator-activated receptors (PPAR), sterol regulatory elementbinding proteins (SREBP), transmembrane 6 superfamily member 2 (TM6SF2), microsomal triglyceride transfer protein (MTTP), tumor necrosis factors-alpha (TNF-α) and manganese superoxide dismutase (MnSOD) have been reported to be related to NAFLD and CAD.
|
26965314 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The adiponectin -11377G and +45G alleles were associated with hypertriglyceridemia in NAFLD patients.
|
18565022 |
2008 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The risk of NAFLD significantly increased in patients with adiponectin gene promoter-11377C/G (CG) genotype [odds ratio (OR)NAFL = 2.5278; ORNASH = 6.1823; ORNAFHC = 17.8570), in those with -11377C/G (GG) genotype (ORNAFL = 2.5900; ORNASH = 6.4017; ORNAFHC = 18.9023), in those with GPx-1 gene C594T (CT) genotype (ORNAFL = 2.6687; ORNASH = 6.7772; ORNAFHC = 22.2063), and in those with C594T (TT) genotype (ORNAFL = 2.6330; ORNASH = 6.4729; ORNAFHC = 21.5682).
|
26897098 |
2016 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
CTD_human |
Adiponectin generally predicts steatosis grade and severity of NAFLD, but it remains to be addressed to what extent this is a direct effect or related to the presence of more severe IR.
|
20415685 |
2010 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thus, the aim of this research will be to evaluate the effect of supplementation with total anthocyanin-base standardized cornelian cherry fruit extract on liver function (Serum levels of Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), cytokeratin-18 fragment M30 (CK-18 M30), as well as steatosis and fibrosis of liver), tumor necrosis factor α (TNF-α), malondealdehyde (MDA), and adiponectin in patients with NAFLD.
|
31324181 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Adiponectin and leptin have evolved as crucial signals in many obesity-related pathologies including non-alcoholic fatty liver disease (NAFLD).
|
28758929 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Multivariate logistic regression analysis showing variables at entry independently associated with NAFLD after 3 years was adiponectin (P < 0.01), sex (P < 0.01), BMI (P < 0.001), insulin (P < 0.001), HOMA-IR (P < 0.01), GGT (P = 0.001), TG (P < 0.001), and WBC (P < 0.001).
|
30390352 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of adiponectin receptors in NAFLD progression remains still unclear.
|
21240660 |
2011 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Forkhead box O1 (FoxO1) and adiponectin (APN) have been proposed to play an important role in the processes in NAFLD in T1DM.
|
30186875 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Obese people with healthy livers are characterized by intact glucose homoeostasis, lower pro-inflammatory cytokine levels, and higher adiponectin and leptin concentrations compared with obese people with NAFLD.
|
30266576 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The lean-with-NAFLD group had significantly higher HOMA-IR (p<0.001) and lower serum adiponectin (p<0.05) than the overweight-without-NAFLD group.
|
29425212 |
2018 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
As an integrator of inflammatory pathway networks, nuclear factor-kappa B (NF-κB) regulates expression of pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin 6 (IL-6), and anti-inflammatory cytokines, such as adiponectin in NAFLD.
|
29037210 |
2017 |
|
Non-alcoholic Fatty Liver Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum adiponectin concentrations were decreased in both NAFLD groups compared to controls (P<0.001 for both groups) The metabolomics study revealed a potential role for various lysophosphatidylcholines (lyso-PC C18:0, lyso-PC C17:0) and phosphatidylcholines (PCaa C36:3; false discovery rate (FDR)-corrected P-value<0.001) as well as lysine, tyrosine, and valine (FDR<0.001).
|
27527746 |
2017 |